
This episode discusses the role of SGLT2 inhibitors in protecting against cancer therapy-related cardiac dysfunction with Dr. Manu Murali Mysore.
CardioNerds ( Drs. Natalie Marrero , Shivani Reddy , and Rebecca S. Steinberg ), discuss the role of SGLT2i in cancer therapy-related cardiac dysfunction (CTRCD) with Dr. Manu Murali Mysore . This episode was produced as part of the CardioNerds Academy curriculum by House Taussig under the guidance of House Chief, Dr. Natalie Marrero , and Academy Program Director, Dr. Gurleen Kaur . A matching review article will be published in US Cardiology Review , the official journal of CardioNerds. Audio editing for this episode was performed by CardioNerds Intern,  Dr. Julia Marques Fernandes . Summary: Cancer therapy-related cardiac dysfunction (CTRCD) spans a spectrum from subclinical biomarker elevation to overt heart failure, with risk amplified by preexisting cardiovascular disease, diabetes, hypertension, obesity, and exposure to therapies, such as anthracyclines, HER2-targeted therapies, or radiation. This episode explores the emerging and promising role of SGLT2 inhibitors as a cardioprotective adjunct in cardio-oncology — examining mechanisms, clinical evidence, ongoing trials, and critical knowledge gaps — while affirming that guideline-directed medical therapy remains the…
Hosts: Dr. Natalie Marrero, Dr. Shivani Reddy, Dr. Rebecca S. Steinberg
Guest: Dr. Manu Murali Mysore
Organizations: CardioNerds, House Taussig, US Cardiology Review, CardioNerds Academy, Circulation
Explore listener stats, chart rankings, contacts and more on the Cardionerds: A Cardiology Podcast podcast page.